the First People's Hospital of Chenzhou
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 6
- 主要终点
- Disease Activity Score in 28 Joints (DAS28)
研究概览
简要总结
between March 2013 and March 2014, Rhupus patients were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.
详细描述
between March 2013 and March 2014, patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) >5.1 were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Rhupus patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) >5.1
排除标准
- •those who had participated in other studies
研究组 & 干预措施
Rhupus syndrome, SLE without RA
Rhupus syndrome, SLE without RA
干预措施: etanercept (Drug)
结局指标
主要结局
Disease Activity Score in 28 Joints (DAS28)
时间窗: 24 week
次要结局
未报告次要终点
研究者
Yang Beibei
the First People's Hospital of Chenzhou
First People's Hospital of Chenzhou
